Intellectual Property

Intellectual property disputes take place on a daily basis in a variety of venues. From an employee’s right to a patent of company-developed products to patent wars between international companies for illegal use of a product/logo, the National Law Review is a great resource for updates on all things IP. The site covers litigation at the United States Patent and Trademark Office (USPTO) and the  Patent Trial and Board Appeals (PTAB), as well as cases in front of the International Trade Commission (ITC) for international patent disputes. The National Law Review covers cases heard by the Supreme Court of the United States (SCOTUS), or appeals which are now sitting in front of the patent-board on Inter partes review (IPR). Additionally, the National Law Review covers cases and decisions of the Federal Trade Commission (FTC).

Copyrights, patent infringement claims, trade secrets, false advertising claims, unfair competition, and intellectual property laws which govern patent-litigation, are all areas which the National Law Review covers, in detail for readers. Patent disputes don’t only occur in the United States. When international countries including the United Kingdom, Brazil, China, India, and the European Union get involved, international laws are also taken into consideration by the PTO. Additionally, information on how to obtain patent protection internationally is also available on the National Law Review.

Intellectual property news on the National Law Review spans from topics including biosimilars, domain name registration, generic top-level domains (gTLDs), drug patents, non-compete agreements, trade secrets, and other industry-related battles which ensue, are covered on the site. Visitors can read about the latest legislation, laws, and news, as it relates to patents and intellectual property in general. Further, visitors to the National Law Review are going to find the latest stories and litigation as it unfolds in front of patent courts across the land. From email and data retention policies, patent disputes over medical devices, cloud computing and artificial intelligence the National Law Review has the details and expert intellectual property litigation legal analysis readers count on.

For hourly updates on the latest news about Intellectual Property Law, IP Litigation, Patent Legislation, and more, be sure to follow our IP Law Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Sort descending Organization
Aug
25
2022
Not “Use It or Lose It”: Even if Unexercised, Director’s Authority over Institution Decisions Remains McDermott Will & Emery
Nov
13
2018
Not-Quite Prior Art Supports Obviousness Of Copaxone Patents In IPR Proceedings Foley & Lardner LLP
Jan
26
2023
Not-So-Open Gaming License: Dungeons & Dragons Publisher Tries to Tighten Grip on Third-Party Content Katten
Aug
31
2021
Nota Bene Episode 141: Artificial Intelligence Technologies: Past, Present, and Forward with Siraj Husain [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Jan
8
2024
Nota Bene Episode 168: How Patent Disputes Affect the Semiconductor Industry [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2019
Nothing Exceptional About Litigation Costs Exceeding Potential Damages McDermott Will & Emery
Jul
1
2019
Nothing Fishy Here: No Private Right Of Action Precludes § 337 Unfair Competition Claim McDermott Will & Emery
May
14
2023
Nothing for free – the real costs of ChatGPT Mintz
Aug
23
2023
Nothing for Free: Federal Circuit Clarifies Commercial Success is All About Sales Foley & Lardner LLP
Feb
23
2023
Nothing Lasts for Everly, Not Even Copyright Co-Authorship Rights McDermott Will & Emery
Aug
31
2023
Nothing Lost in Translation: Book’s Spanish Version Isn’t Different Creative Work McDermott Will & Emery
Apr
25
2023
Nothing More than Empty Words: The Difficulty with Registering Slogans as Trade Marks In the EU K&L Gates
Mar
2
2013
Nothing Non-Obvious About Applying Pre-Existing Technology to the Internet in Intellectual Property Cases McDermott Will & Emery
Sep
22
2022
Nothing Private about Relator’s Qui Tam Action Info McDermott Will & Emery
May
2
2012
Nothing Revealed on “Reveal Day”: New gTLD Application System Remains Suspended Mintz
Jan
2
2015
Nothin’ from Nothin’ Leaves Nothin’: Axiom Worldwide Inc. v. Excite Medical Corp. et al. McDermott Will & Emery
Jan
29
2018
Notice - Its What's Required Sterne, Kessler, Goldstein & Fox P.L.L.C.
Apr
28
2022
Notice Letters, Related Communications May Establish Specific Personal Jurisdiction McDermott Will & Emery
Oct
5
2017
Notice of Appeal Divests PTAB of Jurisdiction McDermott Will & Emery
Sep
16
2021
Notice Under § 287 Means Knowledge of Infringement, Not Knowledge of Patent McDermott Will & Emery
Mar
4
2016
Notification Date of Marketing Approval to be Used in Calculating PTE Duration in Israel Michael Best & Friedrich LLP
Apr
9
2013
NOVARTIS A.G. v. UOI – What is Novelty in Indian Courts? Schwegman, Lundberg & Woessner, P.A.
Apr
21
2017
Novartis AG, LTS et al. v. Noven Pharmaceuticals, Inc. – Prior Judicial Opinions Don’t Bind the PTAB Schwegman, Lundberg & Woessner, P.A.
Jun
22
2022
Novartis v. Accord Redux – Panel 2 Reverses Panel 1 Schwegman, Lundberg & Woessner, P.A.
Jan
10
2022
Novartis v. Accord – No Limits on Negative Limitations? Schwegman, Lundberg & Woessner, P.A.
May
20
2019
Novartis v. West-Ward – Lead Compound Analysis v. Motivation to Combine Schwegman, Lundberg & Woessner, P.A.
Mar
9
2015
Novartis Wins Landmark Biosimilar Approval Schwegman, Lundberg & Woessner, P.A.
Apr
17
2014
Novel Aspect of Invention Determined in Favor of Datascape in Patent Dispute Against Sprint Womble Bond Dickinson (US) LLP
Jun
13
2014
Novel Copyright Action Involving Webcasting and Geofencing to be Decided in Harrisonburg, Virginia Womble Bond Dickinson (US) LLP
Sep
8
2022
Novel Derivative Sovereign Immunity Defense Struck as Forfeited McDermott Will & Emery
Nov
29
2017
November 29, 2017 Update: gTLD Sunrise Periods Now Open Sterne, Kessler, Goldstein & Fox P.L.L.C.
Nov
2
2013
Novozymes Looses “Possession” Of Its Enzyme Re: Patent Litigation Schwegman, Lundberg & Woessner, P.A.
Jan
29
2016
NRT Tech. Corp. et al. v. Everi Payments: Denying Institution of CBM Asserting Patent Ineligibility and Prior Art Under Section 102(e) CBM2015-00167 Faegre Drinker
Sep
22
2020
NSF Will Invest $84 Million in National Nanotechnology Coordinated Infrastructure Bergeson & Campbell, P.C.
Sep
13
2011
NTP Patents Revisited McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins